Annual SG&A
$12.59 M
+$289.00 K+2.35%
31 December 2023
Summary:
Seelos Therapeutics annual selling, general & administrative expenses is currently $12.59 million, with the most recent change of +$289.00 thousand (+2.35%) on 31 December 2023. During the last 3 years, it has risen by +$4.81 million (+61.86%). SEEL annual SG&A is now -17.94% below its all-time high of $15.34 million, reached on 31 December 2012.SEEL Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$2.55 M
-$560.00 K-18.01%
30 June 2024
Summary:
Seelos Therapeutics quarterly selling, general & administrative expenses is currently $2.55 million, with the most recent change of -$560.00 thousand (-18.01%) on 30 June 2024. Over the past year, it has dropped by -$438.00 thousand (-14.66%). SEEL quarterly SG&A is now -67.44% below its all-time high of $7.83 million, reached on 31 December 2021.SEEL Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$1.01 B
+$4.09 M+0.40%
30 June 2024
Summary:
Seelos Therapeutics TTM selling, general & administrative expenses is currently -$1.01 billion, with the most recent change of +$4.09 million (+0.40%) on 30 June 2024. Over the past year, it has dropped by -$1.02 billion (-8111.03%). SEEL TTM SG&A is now -5943.84% below its all-time high of $17.37 million, reached on 30 September 2022.SEEL TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SEEL Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +2.4% | -14.7% | -8111.0% |
| 3 y3 years | +61.9% | +14.5% | -10000.0% |
| 5 y5 years | +58.7% | +80.1% | -8084.4% |
SEEL Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -16.2% | +61.9% | -67.4% | +14.5% | -161.0% | +0.4% |
| 5 y | 5 years | -16.2% | +66.5% | -67.4% | +125.2% | -448.3% | +0.4% |
| alltime | all time | -17.9% | +614.3% | -67.4% | +570.6% | -5943.8% | +21.6% |
Seelos Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2024 | - | $2.55 M(-18.0%) | $11.39 M(-2.0%) |
| Mar 2024 | - | $3.11 M(+13.2%) | $11.62 M(-7.7%) |
| Dec 2023 | $12.59 M(+2.4%) | $2.75 M(-8.1%) | $12.59 M(-0.0%) |
| Sept 2023 | - | $2.99 M(+7.4%) | $12.59 M(+2.7%) |
| June 2023 | - | $2.78 M(-31.7%) | $12.26 M(-0.8%) |
| Mar 2023 | - | $4.07 M(+48.0%) | $12.37 M(+0.6%) |
| Dec 2022 | $12.30 M(-18.1%) | $2.75 M(+3.5%) | $12.30 M(-29.2%) |
| Sept 2022 | - | $2.66 M(-7.7%) | $17.37 M(+2.6%) |
| June 2022 | - | $2.88 M(-27.9%) | $16.94 M(+2.5%) |
| Mar 2022 | - | $4.00 M(-48.9%) | $16.52 M(+10.0%) |
| Dec 2021 | $15.02 M(+93.2%) | $7.83 M(+251.5%) | $15.02 M(+63.2%) |
| Sept 2021 | - | $2.23 M(-9.7%) | $9.21 M(+1.7%) |
| June 2021 | - | $2.46 M(-1.4%) | $9.05 M(+7.0%) |
| Mar 2021 | - | $2.50 M(+24.2%) | $8.46 M(+8.8%) |
| Dec 2020 | $7.78 M(+2.9%) | $2.01 M(-2.8%) | $7.78 M(+12.8%) |
| Sept 2020 | - | $2.07 M(+10.3%) | $6.89 M(+10.5%) |
| June 2020 | - | $1.88 M(+3.3%) | $6.24 M(+3.1%) |
| Mar 2020 | - | $1.82 M(+60.4%) | $6.05 M(-19.9%) |
| Dec 2019 | $7.56 M(-4.7%) | $1.13 M(-20.0%) | $7.56 M(-40.2%) |
| Sept 2019 | - | $1.42 M(-16.3%) | $12.63 M(+4.1%) |
| June 2019 | - | $1.69 M(-49.1%) | $12.13 M(-3.1%) |
| Mar 2019 | - | $3.32 M(-46.5%) | $12.52 M(+10.5%) |
| Dec 2018 | $7.93 M(+10.0%) | $6.21 M(+578.3%) | $11.33 M(+50.4%) |
| Sept 2018 | - | $915.00 K(-55.9%) | $7.54 M(-10.0%) |
| June 2018 | - | $2.08 M(-2.8%) | $8.38 M(+6.0%) |
| Mar 2018 | - | $2.13 M(-11.4%) | $7.90 M(+9.6%) |
| Dec 2017 | $7.21 M(-7.3%) | $2.41 M(+37.3%) | $7.21 M(+7.6%) |
| Sept 2017 | - | $1.76 M(+9.6%) | $6.70 M(+3.2%) |
| June 2017 | - | $1.60 M(+11.2%) | $6.49 M(-7.4%) |
| Mar 2017 | - | $1.44 M(-24.2%) | $7.01 M(-10.0%) |
| Dec 2016 | $7.78 M(-26.0%) | $1.90 M(+22.6%) | $7.80 M(-5.3%) |
| Sept 2016 | - | $1.55 M(-27.0%) | $8.23 M(-9.5%) |
| June 2016 | - | $2.12 M(-4.6%) | $9.10 M(-5.7%) |
| Mar 2016 | - | $2.22 M(-4.9%) | $9.64 M(-8.3%) |
| Dec 2015 | $10.52 M(-7.9%) | $2.34 M(-3.0%) | $10.52 M(-3.9%) |
| Sept 2015 | - | $2.41 M(-9.6%) | $10.94 M(-2.7%) |
| June 2015 | - | $2.67 M(-13.8%) | $11.25 M(-1.8%) |
| Mar 2015 | - | $3.10 M(+12.1%) | $11.46 M(+0.3%) |
| Dec 2014 | $11.42 M(-15.8%) | $2.76 M(+1.6%) | $11.42 M(-2.9%) |
| Sept 2014 | - | $2.72 M(-5.5%) | $11.76 M(-1.2%) |
| June 2014 | - | $2.88 M(-5.9%) | $11.91 M(-6.9%) |
| Mar 2014 | - | $3.06 M(-1.6%) | $12.79 M(-5.7%) |
| Dec 2013 | $13.55 M(-11.6%) | $3.11 M(+8.4%) | $13.55 M(-12.4%) |
| Sept 2013 | - | $2.87 M(-23.7%) | $15.47 M(-5.4%) |
| June 2013 | - | $3.75 M(-1.9%) | $16.36 M(+2.7%) |
| Mar 2013 | - | $3.83 M(-23.9%) | $15.93 M(+3.8%) |
| Dec 2012 | $15.34 M(+33.9%) | $5.03 M(+33.9%) | $15.34 M(+18.9%) |
| Sept 2012 | - | $3.75 M(+13.2%) | $12.90 M(+13.0%) |
| June 2012 | - | $3.32 M(+2.4%) | $11.41 M(-3.1%) |
| Mar 2012 | - | $3.24 M(+25.3%) | $11.78 M(+2.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2011 | $11.45 M(+12.8%) | $2.59 M(+13.9%) | $11.45 M(-5.0%) |
| Sept 2011 | - | $2.27 M(-38.4%) | $12.05 M(+1.5%) |
| June 2011 | - | $3.69 M(+26.9%) | $11.87 M(+9.7%) |
| Mar 2011 | - | $2.91 M(-8.7%) | $10.82 M(+6.6%) |
| Dec 2010 | $10.15 M(+141.9%) | $3.18 M(+52.3%) | $10.15 M(+17.2%) |
| Sept 2010 | - | $2.09 M(-20.9%) | $8.67 M(+18.9%) |
| June 2010 | - | $2.64 M(+17.9%) | $7.29 M(+36.4%) |
| Mar 2010 | - | $2.24 M(+32.0%) | $5.34 M(+27.4%) |
| Dec 2009 | $4.20 M(-26.6%) | $1.70 M(+137.6%) | $4.20 M(-4.6%) |
| Sept 2009 | - | $714.00 K(+2.8%) | $4.40 M(-12.2%) |
| June 2009 | - | $694.70 K(-36.3%) | $5.01 M(-9.1%) |
| Mar 2009 | - | $1.09 M(-42.5%) | $5.51 M(-3.7%) |
| Dec 2008 | $5.72 M(+1.5%) | $1.90 M(+42.9%) | $5.72 M(-5.4%) |
| Sept 2008 | - | $1.33 M(+11.2%) | $6.04 M(+5.0%) |
| June 2008 | - | $1.19 M(-8.4%) | $5.75 M(+0.9%) |
| Mar 2008 | - | $1.30 M(-41.3%) | $5.70 M(+1.3%) |
| Dec 2007 | $5.63 M(+1.1%) | $2.22 M(+114.0%) | $5.63 M(+12.8%) |
| Sept 2007 | - | $1.04 M(-9.3%) | $5.00 M(-0.8%) |
| June 2007 | - | $1.14 M(-7.2%) | $5.04 M(+1.4%) |
| Mar 2007 | - | $1.23 M(-22.1%) | $4.97 M(-10.8%) |
| Dec 2006 | $5.57 M(-19.0%) | $1.58 M(+46.5%) | $5.57 M(-19.3%) |
| Sept 2006 | - | $1.08 M(+0.3%) | $6.90 M(-2.1%) |
| June 2006 | - | $1.08 M(-41.3%) | $7.05 M(-4.7%) |
| Mar 2006 | - | $1.83 M(-37.2%) | $7.40 M(+7.6%) |
| Dec 2005 | $6.88 M(-1.5%) | $2.92 M(+137.3%) | $6.88 M(+10.9%) |
| Sept 2005 | - | $1.23 M(-13.7%) | $6.20 M(-8.5%) |
| June 2005 | - | $1.42 M(+8.7%) | $6.78 M(-2.2%) |
| Mar 2005 | - | $1.31 M(-41.5%) | $6.93 M(-0.7%) |
| Dec 2004 | $6.98 M(+18.3%) | $2.24 M(+24.4%) | $6.98 M(+1.6%) |
| Sept 2004 | - | $1.80 M(+14.2%) | $6.87 M(+9.1%) |
| June 2004 | - | $1.58 M(+16.0%) | $6.29 M(+4.5%) |
| Mar 2004 | - | $1.36 M(-36.2%) | $6.03 M(+2.1%) |
| Dec 2003 | $5.90 M(-2.7%) | $2.13 M(+74.0%) | $5.90 M(+4.6%) |
| Sept 2003 | - | $1.23 M(-6.3%) | $5.64 M(-0.2%) |
| June 2003 | - | $1.31 M(+5.9%) | $5.65 M(-3.9%) |
| Mar 2003 | - | $1.24 M(-34.0%) | $5.89 M(-3.0%) |
| Dec 2002 | $6.07 M(+27.2%) | $1.87 M(+51.2%) | $6.07 M(+7.4%) |
| Sept 2002 | - | $1.24 M(-19.6%) | $5.65 M(+2.2%) |
| June 2002 | - | $1.54 M(+8.9%) | $5.53 M(+8.5%) |
| Mar 2002 | - | $1.41 M(-2.7%) | $5.09 M(+6.7%) |
| Dec 2001 | $4.77 M(+48.6%) | $1.45 M(+30.1%) | $4.77 M(+3.0%) |
| Sept 2001 | - | $1.12 M(+1.2%) | $4.63 M(+8.7%) |
| June 2001 | - | $1.10 M(+1.1%) | $4.26 M(+8.7%) |
| Mar 2001 | - | $1.09 M(-17.0%) | $3.92 M(+22.2%) |
| Dec 2000 | $3.21 M(+82.2%) | $1.32 M(+76.0%) | $3.21 M(+69.6%) |
| Sept 2000 | - | $748.50 K(-2.0%) | $1.89 M(+65.4%) |
| June 2000 | - | $763.60 K(+100.9%) | $1.14 M(+200.9%) |
| Mar 2000 | - | $380.10 K | $380.10 K |
| Dec 1999 | $1.76 M(-3.5%) | - | - |
| Dec 1997 | $1.82 M | - | - |
FAQ
- What is Seelos Therapeutics annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Seelos Therapeutics?
- What is Seelos Therapeutics annual SG&A year-on-year change?
- What is Seelos Therapeutics quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Seelos Therapeutics?
- What is Seelos Therapeutics quarterly SG&A year-on-year change?
- What is Seelos Therapeutics TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Seelos Therapeutics?
- What is Seelos Therapeutics TTM SG&A year-on-year change?
What is Seelos Therapeutics annual selling, general & administrative expenses?
The current annual SG&A of SEEL is $12.59 M
What is the all time high annual SG&A for Seelos Therapeutics?
Seelos Therapeutics all-time high annual selling, general & administrative expenses is $15.34 M
What is Seelos Therapeutics annual SG&A year-on-year change?
Over the past year, SEEL annual selling, general & administrative expenses has changed by +$289.00 K (+2.35%)
What is Seelos Therapeutics quarterly selling, general & administrative expenses?
The current quarterly SG&A of SEEL is $2.55 M
What is the all time high quarterly SG&A for Seelos Therapeutics?
Seelos Therapeutics all-time high quarterly selling, general & administrative expenses is $7.83 M
What is Seelos Therapeutics quarterly SG&A year-on-year change?
Over the past year, SEEL quarterly selling, general & administrative expenses has changed by -$438.00 K (-14.66%)
What is Seelos Therapeutics TTM selling, general & administrative expenses?
The current TTM SG&A of SEEL is -$1.01 B
What is the all time high TTM SG&A for Seelos Therapeutics?
Seelos Therapeutics all-time high TTM selling, general & administrative expenses is $17.37 M
What is Seelos Therapeutics TTM SG&A year-on-year change?
Over the past year, SEEL TTM selling, general & administrative expenses has changed by -$1.02 B (-8111.03%)